Organoids Derived From Patients Provide a New Opportunity for Research and Individualized Treatment of Malignant Peritoneal Mesothelioma

The authors established a new potential preclinical model for malignant peritoneal mesothelioma (MPM) using patient-derived MPM organoids and to comprehensively evaluate the practicality of this model in medical research and its feasibility in guiding individualized patient treatment.